Table 1.
Demographics, Pathology Laboratory results, and vascular injury panel results of healthy individuals and colorectal cancer (CRC) patients.
| Demographics | ||||||
|---|---|---|---|---|---|---|
| Healthy individuals | CRC patients | |||||
| Gender | Male (n = 16), Female (n = 25) | Male (n = 13), Female (n = 13) | ||||
| Age (years) | 50 [44–56.5] | 56.5 [46.25–67.5] | ||||
| Pathology Laboratory results | ||||||
| Reference (normal) | Healthy individuals (n = 40) | CRC patients (n = 26) | Unadjusted OR (99.8% CI) | Adjusted OR (99.8% CI) | Ordinal OR (99.8% CI) | |
| Total cholesterol (mmol L−1) | <5.0 | 5.3 [4.6–5.8] | 4 [2.98–5.08] | 0.42076 (0.16054–0.84944) | 0.41326 (0.14649–0.86124) | 0.45806 (0.21885–0.85567) |
| HDL cholesterol (mmol L−1) | >1.2 | 1.4 [1.2–1.6] | 0.9 [0.73–1.08] | 0.0036712 (1.6763 × 10−5–0.11499) | 0.00070242 (2.5039 × 10−7–0.063268) | 0.013985 (0.00045301–0.18081) |
| LDL cholesterol (mmol L−1) | <3.0 | 3.2 [2.5–3.8] | 2.55 [1.65–3.35] | 0.50688 (0.1926–1.0978) | 0.51151 (0.18674–1.1181) | 0.50247 (0.2148–1.0681) |
| Triglyceride (mmol L−1) | <1.70 | 1.37 [0.95–1.94] | 1.45 [0.95–1.69] | 0.61177 (0.14169–1.7216) | 0.52288 (0.1038–1.5875) | 0.6475 (0.16181–1.7703) |
| Non-HDL cholesterol (mmol L−1) | <3.8 | 3.8 [3.1–4.6] | 3.25 [2.33–4] | 0.55199 (0.22654–1.1447) | 0.55252 (0.22059–1.1556) | 0.54693 (0.245–1.1199) |
| Total cholesterol/HDL cholesterol ratio |
<4.0 >4 – moderate risk >5 – high CVD risk |
3.7 [3.2–4.3] | 4.6 [4.13–5.48] | 1.9225 (0.99881–5.0375) | 2.0944 (1.0311–5.7913) | 1.853 (1.0502–3.7879) |
| Ultrasensitive CRP (mg L−1) |
<1 <1 – low risk 1–3 – moderate risk >3 – high risk >5.0 – consider active infection/inflammation |
1.6 [0.74–3.18] | 56.77 [8.41–119.77] | 1.9276 (1.1709–5.0789) | 1.9885 (1.1844–5.2185) | 1.0173 (1.0045–1.0333) |
| Vascular injury panel results | ||||||
| Biomarker | Reference (normal) | Healthy individuals (n = 40) | CRC patients (n = 26) | Unadjusted OR (99.8% CI) | Adjusted OR (99.8% CI) | Ordinal OR (99.8% CI) |
| SAA (μg mL−1) | 1–5 | 1.55 [0.77–2.51] | 25.5 [5.85–256.23] | 1.041 (1.008–1.1663) | 1.04 (1.0081–1.1594) | 1.0091 (1.0014–1.0178) |
| CRP (μg mL−1) | <1 | 1.34 [0.55–3.06] | 56.19 [8.28–125] | 1.1537 (1.0311–1.5018) | 1.1459 (1.0297–1.4963) | 1.0232 (1.0082–1.0414) |
| sVCAM-1 (μg mL−1) | 0.39 [0.31–0.45] | 0.43 [0.34–0.54] | 141.85 (0.43296–293214) | 104.95 (0.21565–319110) | 135.44 (0.7473–50350) | |
| sICAM-1 (μg mL−1) | 0.1–0.408 | 0.29 [0.24–0.34] | 0.56 [0.38–0.76] | 400925647 (1274.2–1.2605 × 1019) | 1230573039 (1465.2–1.7109 × 1020) | 151.71 (6.1794–14694) |
Data expressed as median and [25−75% quartile range]. Significant differences are shown in bold for all models. All CRC patients with hypertension used medication for blood pressure regulation. Prescribed medication was recorded, and included Enalapril, Ridaq, Atenolol, Amlodipine, LASIX (furosemide), Losartan, and Perindopril.